Regulatory approval

Published by the Health Service Executive. Approved

HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours >2cm in diameter.

This is written in the approval document.

Reimbursement

Hospital

Citation

Trastuzumab Subcutaneous 21 days - Early Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6700/285_v4_Trastuzumab_SC_21days_EBC.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) HER2-positive Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
HSE (1) ERBB2 amplification Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab

Contributions

Date Contributor Description
2026-08-02 Van Allen lab Initial curation of into moalmanac-db
2024-01-16 Van Allen lab Adding HSE approvals for reimbursement to database
2015-09-15 Health Service Executive Indication approved for reimbursement.